STRATFix: Enabling stratified medicine with novel fixatives for improved pre-analytical pathology workflows

STRATFix：利用新型固定剂实现分层医学，以改进分析前病理学工作流程

• 批准号: 101867
• 金额: $ 138.38万
• 依托单位: QIAGEN MANCHESTER LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101867
• 关键词: STRATFix; Enabling; stratified; medicine; novel

After many decades of cancer research, treatment is increasingly changing to become more tailored to individual patients' needs (often referred to as 'personalised' or 'stratified' medicine). Current preparation methods that allow microscopic assessment of cells and tissue do not preserve nucleic acids well enough for the latest genetic tests that are necessary for personalised medicine. Our study aims to improve the preparation of tissue and cell samples, and nucleic acids from patient's blood, so that the full range of microscopic and genetic test results can be obtained to help select the right treatment for individual patients. Our business partner QIAGEN is market leader in providing tools for sample collection, stabilisation and nucleic acid purification. QIAGEN is developing new solutions to preserve cells in aspirated (FNA) samples and blood. By working in a UK-wide collaboration, we have access to the widest possible range of blood, cell and tissue types. Because these developments will take place in multiple major, opinion-leading UK hospitals, we have the greatest likelihood that the project outcomes will be adopted by the whole UK pathology community.

经过数十年的癌症研究，治疗方法日益发生变化，更加适合个体患者的需求（通常称为“个性化”或“分层”医学）。目前允许对细胞和组织进行显微镜评估的制备方法不能很好地保存核酸，无法满足个性化医疗所需的最新基因测试的要求。我们的研究旨在改进组织和细胞样本以及患者血液核酸的制备，以便获得全方位的显微镜和基因检测结果，以帮助为个体患者选择正确的治疗方法。我们的业务合作伙伴 QIAGEN 是提供样品采集、稳定和核酸纯化工具的市场领导者。 QIAGEN 正在开发新的解决方案来保存抽吸 (FNA) 样本和血液中的细胞。通过在英国范围内的合作，我们可以获得尽可能广泛的血液、细胞和组织类型。由于这些进展将在多个主要的、意见领先的英国医院进行，因此我们很有可能该项目成果将被整个英国病理学界采用。